- Home
- RYTM vs PTEN Comparison
RYTM vs PTEN Comparison
Compare RYTM & PTEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYTM
- PTEN
- Stock Information
- Founded
- RYTM 2008
- PTEN 1978
- Country
- RYTM United States
- PTEN United States
- Employees
- RYTM N/A
- PTEN N/A
- Industry
- RYTM Biotechnology: Pharmaceutical Preparations
- PTEN Oil & Gas Production
- Sector
- RYTM Health Care
- PTEN Energy
- Exchange
- RYTM Nasdaq
- PTEN Nasdaq
- Market Cap
- RYTM 3.1B
- PTEN 3.0B
- IPO Year
- RYTM 2017
- PTEN 1993
- Fundamental
- Price
- RYTM $56.12
- PTEN $7.68
- Analyst Decision
- RYTM Strong Buy
- PTEN Buy
- Analyst Count
- RYTM 10
- PTEN 13
- Target Price
- RYTM $65.80
- PTEN $12.04
- AVG Volume (30 Days)
- RYTM 552.7K
- PTEN 9.4M
- Earning Date
- RYTM 11-05-2024
- PTEN 02-12-2025
- Dividend Yield
- RYTM N/A
- PTEN 4.17%
- EPS Growth
- RYTM N/A
- PTEN N/A
- EPS
- RYTM N/A
- PTEN N/A
- Revenue
- RYTM $112,530,000.00
- PTEN $5,800,093,000.00
- Revenue This Year
- RYTM $63.64
- PTEN $34.14
- Revenue Next Year
- RYTM $42.98
- PTEN N/A
- P/E Ratio
- RYTM N/A
- PTEN N/A
- Revenue Growth
- RYTM 81.55
- PTEN 73.11
- 52 Week Low
- RYTM $35.17
- PTEN $7.15
- 52 Week High
- RYTM $68.58
- PTEN $12.65
- Technical
- Relative Strength Index (RSI)
- RYTM 46.95
- PTEN 46.05
- Support Level
- RYTM $53.39
- PTEN $7.19
- Resistance Level
- RYTM $57.27
- PTEN $7.66
- Average True Range (ATR)
- RYTM 2.32
- PTEN 0.34
- MACD
- RYTM -0.55
- PTEN -0.05
- Stochastic Oscillator
- RYTM 33.21
- PTEN 41.09
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
About PTEN Patterson-UTI Energy Inc.
Patterson-UTI Energy is one of the largest land rig drilling contractors in the United States. Its 2023 merger with NexTier greatly expanded its pressure pumping operations, as well, and the firm now controls nearly 20% of the North American market for drilling and completions services. It also provides directional drilling services and tool rental services in most US onshore oil and gas basins.